Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Hsp90B in Bladder Cancer

Funder: National Cancer Institute

Funding period
USD 365 K
Funding amount
Abstract
The development of new methods to treat cancer is greatly needed. The Hsp90 protein folding machinery has been the target of significant interest for the development of anti-cancer agents. However, Hsp90 is responsible for the folding of ~300 protein folding substrates, which may lead to undesired on-target toxicity and may be responsible for many of the Hsp90-targeted drugs that have failed in clinical trials. Through a structure-based approach, an isoform-selective inhibitor of Hsp90 has been identified and shown to exhibit good selectivity and affinity against particular cancers. Consequently, the goal of this application is to optimize this new inhibitory scaffold for great affinity/efficacy, to evaluate the role of a specific Hsp90 isoform in cancer, and to validate this isoform as a target for the treatment of bladder cancer.
Similar projects All >
Sorted by: Start Date
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2019
Project list item
Notch in bladder cancer: oncogene and tumour suppressor

Canadian Cancer Society to Peter Black, Colin Collins, Mads Daugaard, Yuzhuo Wang

USD 758,595
2016 - 2020
Project list item
Determinants of T-Cell Activity in Bladder Cancer

Congressionally Directed Medical Research Programs to Vivek K Arora

USD 549,000
2015 - 2016
Project list item
The new strategy for urothelial carcinoma by inhibiting autophagy

Japan Society for the Promotion of Science to Keishiro Fukumoto, Eiji Kikuchi

USD 34,348
2015 - 2017
Project list item
A treatment strategy targeting ERBB2 to overcome chemoradiation resistance in muscle-invasive bladder cancer

Japan Society for the Promotion of Science to Masaharu INOUE

USD 33,637
2014 - 2017

System

Categories
  • FOR (ANZSRC)

    0601 Biochemistry and Cell Biology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Orphan Drug

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science